Skip to main content
Premium Trial:

Request an Annual Quote

EPI Gains $150K NCI Grant for Breast Cancer Biomarker Dx

NEW YORK (GenomeWeb News) – Expression Pathology plans to use a $148,000 grant from the National Cancer Institute to identify biomarkers and develop breast cancer diagnostic technology, the company said today.
 
Gaithersburg, Md.-based EPI said it will use the Small Business Innovation Research grant to use its microproteomics technologies to identify protein biomarkers of metastasis in primary breast cancer.
 
The company expects its Liquid Tissue sample preparation and Director laser microdissection will enable mass spectrometry-based proteomic profiling of archived formalin-fixed tissue.
 
“Our aim is to develop valuable tissue protein assays that can aid patient treatment decisions, and to identify new therapeutic targets and companion diagnostics to those targets,” explained EPI Chief Scientific Officer David Krizman.
 
The company also said in a statement that FFPE tissues are “a huge, untapped resource for discovery, validation, and measurement of valuable biomarkers of disease progression, drug response, and toxicity.”

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.